CD19 and non-Hodgkin lymphoma: Chimeric antigen receptor T (CAR T)-cell therapy, and in particular CD-19 CAR T-cells, has recently been proven to be highly effective in the treatment of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) (e.g., tisagenlecleucel/Kymriah, axicabtagene ciloleucel/Yescarta, lisocabtagene/Breyanzi, brexucabtagene/Tecartus) [122,123,124,125,126].